What is the main business of WD Pharma?

The main business activity of WD Pharma focuses on other research and experimental development on natural sciences and engineering.

When was the company founded?

The company was registered in the Polish National Court Register (KRS) on February 20, 2012.

Where is the headquarters located?

The headquarters is located at: Suwalska 8, 03-252 Warszawa.

Who is on the management board?

The management board consists of: Andrzej Wyrzykowski (President of the Management Board).

What is the share capital?

The share capital of the company is PLN 3,515,000 (approx. $949,487).

What period do the latest financial data cover?

The latest available financial statement covers the period from January 1, 2024 to December 31, 2024.

What was the revenue?

In 2024, the company generated total revenue of $157,385, representing an increase of 0.0% compared to 2023.

Yes, the company recorded a net profit of $9,923 in 2024, meaning the company decreased its profit by 3.0%.

Which cost dominates operating expenses?

The largest operating cost category falls under external services. This category amounted to $804 in 2024, representing 100% of all operating expenses.

WD Pharmasp. z o.o.

Other research and experimental development on natural sciences and engineering

KRS: NIP: REGON:

Overview

Status

Active

Registry date

2012-02-20

Share capital

3,515,000.00 PLN

Registered address

Suwalska 8/177, 03-252 Warszawa, Poland

Electronic delivery address

AE:PL-80876-53749-HWBGC-18

Financials

Revenue history (in k)

Filing timeliness

2 of 6 financial statements were filed late (the longest delay 361 days for 2023), 1 not filed.

202509/07/2026
202411/07/2025
202311/07/2025
2022not filed
202112/10/2022
202030/09/2021

Filed on timeDelayFiling deadline

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Statistics

How the company ranks by revenue within its industry, region and across Poland in 2025.

Results vs industry

Revenue

This companyUSD 157.74kMedianUSD 73.26kAverageUSD 3.23m

Net profit

This companyUSD 10.20kMedianUSD 68.58AverageUSD 82.17k

Operating costs

This companyUSD 777.25MedianUSD 75.78kAverageUSD 3.04m

Assets

This companyUSD 7.86mMedianUSD 119.88kAverageUSD 3.90m

Industry

Authorized Representatives

Andrzej Wyrzykowski – President of the Management Board

Wioletta Jadwiga Zdańska – Attorney-in-fact (sole)

Manner of representation

Each member of the management board is authorized to make declarations on behalf of the company independently.

Ownership

Owner	Shares	Share value	Stake
Alims Kutkins	34,799	$470,002.70	49.5007%
Andrzej Wyrzykowskiage 75	34,798	$469,989.20	49.4993%
Others	703	$9,494.87	1%

Beneficial owners

Person	Rights

Subsidiaries

	Name	Share value	Stake
	Celther Polskasp. z o.o.	21,609.94 USD	80%
	Przedsiębiorstwo Farmaceutyczne Lek-Am Investmentssp. z o.o.	675.31 USD	50%

Bank accounts

Registered as a VAT taxpayer on 2012-04-10.

No bank accounts reported to the VAT Taxpayer Register.

Debt

No entries in the National Debtors Register (KRZ).

Public aid

No public aid cases recorded in the last 10 years.

Competitors

Name	Revenue	Website
MedicalgorithmicsS.A.	$7,566,549.47	medicalgorithmics.com
Clinchoicesp. z o.o.	$2,048,208.30	clinchoice.com
Retailicsp. z o.o.	$637,675.32	retailic.com
Centrum Wsparcia Innowacjisp. z o.o.	$219,683.86	cwin.pl
Pharmaxi Polandsp. z o.o.	$152,292.34	pharmaxi.com.ua
Omega Innovationssp. z o.o.	$110,004.52	omegainnovations.eu
Cezamat Pwsp. z o.o.	$119,656.05	cezamat.eu
Recometalsp. z o.o.	$114,425.74	recometal.pl
Bacteromicsp. z o.o.	$112,732.71	bacteromic.com
CPJS - Centrum Promocji Jakości Stalisp. z o.o.	$90,239.54	epstal.pl

Change history

Date	Event
2016-04-18	Share capital increase (5,000.00 PLN → 3,515,000.00 PLN)
2015-06-24	PKD change (Removed: 72.1; Added: 64.99.Z, 72.19.Z)
2015-03-01	Business resumed
2014-03-01	Business suspended
2012-02-20	Entered in the register

FAQ

Last updated: 2026-07-15